Pharmaceutical
Filter News
Found 55,980 articles
-
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults
3/24/2022
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age.
-
Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer
3/24/2022
Eli Lilly and Company announced that the U.S. Food and Drug Administration has issued a complete response letter for the Biologics License Application for the investigational medicine sintilimab injection, a PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer.
-
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/24/2022
89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, reported its financial results for the quarter and full year ended December 31, 2021.
-
Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution
3/24/2022
Sosei Group Corporation confirms that a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately.
-
Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022
3/24/2022
Sensorion announces that the Company’s shareholders are invited to participate in the Extraordinary General Meeting, to be held on Thursday, April 14th, 2022, at 2 pm CET in the premises of the hotel L’Arcade, located at 9 rue de l’Arcade, 75008, Paris.
-
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
3/24/2022
Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T.
-
Innate Pharma Reports Full Year 2021 Financial Results and Business Update
3/24/2022
Innate Pharma SA reported its consolidated financial results for the year ending December 31, 2021.
-
Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons
3/24/2022
Persica Pharmaceuticals Ltd announces that Peter Hamlyn, founding member and Non-Executive Director of Persica will be presenting at the 2022 British Association of Spine Surgeons meeting, taking place in Belfast on 23-25 March 2022.
-
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences
3/24/2022
Addex Therapeutics announced that CEO, Tim Dyer, will present at both the Bio-Europe Spring 2022 Conference and the Maxim Group – 2022 Virtual Growth Conference taking place March 28 - 31, 2022 and March 28 – 30, 2022, respectively.
-
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering
3/24/2022
Statera Biopharma, Inc. announced the closing of its previously announced underwritten public offering of 12,555,555 units, at a price to the public of $0.45 per Unit for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses.
-
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
3/24/2022
Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, provides a business update and reports financial results for the quarter and full year ended December 31, 2021.
-
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
3/24/2022
Cytokinetics, Incorporated announced four presentations at the American College of Cardiology 71st Annual Scientific Session & Expo taking place in Washington, D.C. from April 2, 2022 - April 4, 2022.
-
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
3/24/2022
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that Philip R. Krause, M.D. has joined its Board of Directors.
-
Arcus Biosciences Announces New Employment Inducement Grants - Mar 24, 2022
3/24/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eleven new employees options to purchase a total of 30,950 shares of the Company’s common stock at an exercise price per share of $32.98, which was the closing price on March 23, 2022, and restricted stock units to acquire a total of 15,475 shares of the Company’s common stock.
-
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/24/2022
Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the fourth quarter and full year ended December 31, 2021, and a corporate update.
-
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
-
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age.
-
Pfizer is lining up a potential New Drug Application for an ulcerative colitis treatment for patients who are not seeing an improvement in their condition from currently available options.
-
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
-
Pfizer issued a statement on Monday regarding a voluntary recall of three of its products. The recall affects eleven lots of hypertension medications in total.